Proactive Acquisition of an Oral Therapy for Hypophosphatasia

BioMarin Pharmaceutical (BMRN) has entered into a definitive agreement to acquire Alesta Therapeutics for a total of $490 million, aiming to strengthen its pipeline of rare bone disease treatments. The core of this deal involves an upfront payment of $275 million and potential future milestone payments of $215 million, granting BioMarin exclusive rights to Alesta's lead asset, ALE1, an oral small molecule compound for hypophosphatasia (HPP). ALE1 works by normalizing levels of inorganic pyrophosphate (PPi), which interferes with mineralization of bones and teeth. Clinical trials for ALE1 are scheduled to begin in September 2025, targeting adult patients with HPP. BioMarin strategically focused on acquiring only the ALE1 asset, excluding Alesta's existing employees and other pipeline assets, to enhance operational efficiency and concentrate on the target disease.

Challenging AstraZeneca's Dominance

The current market for HPP treatments is largely dominated by Strensiq (asfotase alfa), an enzyme replacement therapy (ERT) administered via subcutaneous injection, developed by AstraZeneca's (AZN) subsidiary, Alexion. With an annual treatment cost of approximately $1 million per patient, Strensiq has achieved significant commercial success, generating $517 million in revenue in the first quarter of 2026 alone. However, the frequent administration schedule of 3-6 times per week, along with injection site pain, presents significant drawbacks in terms of patient convenience, creating a substantial unmet medical need. BioMarin's ALE1 aims to be the first-in-class oral therapy, and if successfully commercialized, it has the potential to be a game-changer, significantly eroding AstraZeneca's market share.

Targeting the Gap in the Adult HPP Market

Strensiq has only been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of HPP in pediatric and infantile patients, leaving a gap in the treatment of adult patients. AstraZeneca conducted a Phase 3 clinical trial for its next-generation ERT candidate, ALXN1850, to expand into the adult market, but the trial failed to meet its primary endpoint in patients aged 12 years and older, significantly hindering its expansion plans. In contrast, Alesta designed its Phase 1/2 clinical trial for ALE1 to include adult HPP patients from the outset, directly targeting this market gap. BioMarin is proactively seeking to capture the underserved adult HPP market, diversifying its portfolio in the rare disease space.

Restoring Leadership in Bone Disorders After Past Setbacks

BioMarin's investment is viewed as an aggressive move to overcome past clinical failures in rare disease assets and re-establish its position as a leader in bone disorders. Last year, BioMarin acquired Inozyme for $270 million, securing an injectable therapy for ENPP1 deficiency, but the Phase 3 trial failed to demonstrate significant efficacy, leading to the recent discontinuation of development. However, undeterred, BioMarin quickly secured ALE1 to provide momentum to its bone disorders business unit, which was established in 2024.

With Voxzogo, a blockbuster drug for achondroplasia, already generating significant annual revenue, BioMarin is well-positioned to leverage its global sales network to accelerate the market penetration of ALE1. This acquisition is expected to enable BioMarin to rebuild the strongest portfolio in the rare bone disease segment to compete with AstraZeneca.